POOLBEG PHARMA was spun off from Open Orphan as it did not quite fit into that company’s developmental model as it is targeting the burgeoning infectious disease market, which in the wake of the Covid-19 pandemic is set to be a fast-growing sector, with an expected value of $250bn (€249bn). A planned licensing deal for the… Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!